Price Action To Observe: It Seems XBiotech Inc Will Go Up. Have Another Big Increase

Price Action To Observe: It Seems XBiotech Inc Will Go Up. Have Another Big Increase

The stock of XBiotech Inc (NASDAQ:XBIT) is a huge mover today! About 218,329 shares traded hands or 102.43% up from the average. XBiotech Inc (NASDAQ:XBIT) has risen 25.98% since April 14, 2016 and is uptrending. It has outperformed by 21.29% the S&P500.
The move comes after 6 months positive chart setup for the $550.04 million company. It was reported on Nov, 16 by Barchart.com. We have $26.63 PT which if reached, will make NASDAQ:XBIT worth $379.53 million more.

According to Zacks Investment Research, “XBiotech Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing True Human(TM) monoclonal antibodies for treating diseases. XBiotech Inc. is based in AUSTIN, United States.”

More recent XBiotech Inc (NASDAQ:XBIT) news were published by: Fool.com which released: “Why XBiotech Inc. Fell 33% Today” on July 05, 2016. Also Fool.com published the news titled: “Why XBiotech Inc. Made a U-Turn Today” on December 08, 2015. Marketwatch.com‘s news article titled: “XBiotech Inc. NASDAQ: XBIT” with publication date: April 15, 2015 was also an interesting one.

XBIT Company Profile

XBiotech Inc., incorporated on October 23, 2005, is a clinical-stage biopharmaceutical company. The Firm is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Firm focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Firm has also developed a True Human monoclonal antibody discovery platform and manufacturing system. The Company’s therapeutic antibody, Xilonix, is being evaluated as a monotherapy to treat advanced stages of colorectal cancer. Xilonix neutralizes a pro-inflammatory protein produced by leukocytes and other cells, interleukin-1 alpha (IL-1a).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment